Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy

Frontiers in Cardiovascular Medicine - Tập 9
Shigeru Miyagawa1, Satoshi Kainuma1, Takuji Kawamura1, Kota Suzuki1, Yoshito Ito1, Hiroko Iseoka1, Emiko Ito1, Maki Takeda1, Masao Sasai1, Noriko Mochizuki‐Oda1, Tomomi Shimamoto1, Yukako Nitta1, Hiromi Dohi2, Tadashi Watabe3, Yasushi Sakata4, Köichi Toda1, Yoshiki Sawa1
1Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Japan
2Center for iPS cell Research and Application, Kyoto University, Kyoto, Japan
3Department of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Suita, Japan
4Department of Cardiology, Osaka University Graduate School of Medicine, Suita, Japan

Tóm tắt

Despite major therapeutic advances, heart failure, as a non-communicable disease, remains a life-threatening disorder, with 26 million patients worldwide, causing more deaths than cancer. Therefore, novel strategies for the treatment of heart failure continue to be an important clinical need. Based on preclinical studies, allogenic human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) patches have been proposed as a potential therapeutic candidate for heart failure. We report the implantation of allogeneic hiPSC-CM patches in a patient with ischemic cardiomyopathy (ClinicalTrials.gov, #jRCT2053190081). The patches were produced under clinical-grade conditions and displayed cardiogenic phenotypes and safety in vivo (severe immunodeficient mice) without any genetic mutations in cancer-related genes. The patches were then implanted via thoracotomy into the left ventricle epicardium of the patient under immunosuppressive agents. Positron emission tomography and computed tomography confirmed the potential efficacy and did not detect tumorigenesis in either the heart or other organs. The clinical symptoms improved 6 months after surgery, without any major adverse events, suggesting that the patches were well-tolerated. Furthermore, changes in the wall motion in the transplanted site were recovered, suggesting a favorable prognosis and the potential tolerance to exercise. This study is the first report of a successful transplant of hiPSC-CMs for severe ischemic cardiomyopathy.

Từ khóa


Tài liệu tham khảo

Cohn, 2014, Continue what we are doing to treat HF, but do it better, Nat Rev Cardiol., 11, 69, 10.1038/nrcardio.2013.212

Longnus, 2014, Heart transplantation with donation after circulatory determination of death, Nat Rev Cardiol., 11, 354, 10.1038/nrcardio.2014.45

Abraham, 2013, Devices in the management of advanced, chronic heart failure, Nat Rev Cardiol., 10, 98, 10.1038/nrcardio.2012.178

Takahashi, 2006, Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors, Cell., 126, 663, 10.1016/j.cell.2006.07.024

Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell., 131, 861, 10.1016/j.cell.2007.11.019

Kawamura, 2012, Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model, Circulation., 126, S29, 10.1161/CIRCULATIONAHA.111.084343

Miyagawa, 2021, Evaluation of the efficacy and safety of a clinical grade human induced pluripotent stem cell-derived cardiomyocyte patch: a pre-clinical study, bioRxiv [Preprint]., 10.1101/2021.04.07.438744

Nakagawa, 2014, A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells, Sci Rep., 4, 3594, 10.1038/srep03594

Ito, 2021, Efficient method to dissociate induced pluripotent stem cell-derived cardiomyocyte aggregates into single cells, Methods Mol Biol., 2320, 29, 10.1007/978-1-0716-1484-6_4

Ito, 2019, Tumorigenicity assay essential for facilitating safety studies of hiPSC-derived cardiomyocytes for clinical application, Sci Rep., 9, 1881, 10.1038/s41598-018-38325-5

Shiba, 2016, Allogeneic transplantation of iPS cell-derived cardiomyocytes regenerates primate hearts, Nature., 538, 388, 10.1038/nature19815

Patila, 2015, Comparison of arrhythmogenicity and proinflammatory activity induced by intramyocardial or epicardial myoblast sheet delivery in a rat model of ischemic heart failure, PLoS ONE., 10, e0123963, 10.1371/journal.pone.0123963

Higuchi, 2015, Functional and electrical integration of induced pluripotent stem cell-derived cardiomyocytes in a myocardial infarction rat heart, Cell Transplant., 24, 2479, 10.3727/096368914X685799

Iseoka, 2018, Pivotal role of non-cardiomyocytes in electromechanical and therapeutic potential of induced pluripotent stem cell-derived engineered cardiac tissue, Tissue Eng Part A., 24, 287, 10.1089/ten.tea.2016.0535

Bolli, 1999, Molecular and cellular mechanisms of myocardial stunning, Physiol Rev., 79, 609, 10.1152/physrev.1999.79.2.609

Fallavollita, 1997, Circulation., 95, 1900, 10.1161/01.CIR.95.7.1900

Yoshida, 2020, Syngeneic mesenchymal stem cells reduce immune rejection after induced pluripotent stem cell-derived allogeneic cardiomyocyte transplantation, Sci Rep., 10, 4593, 10.1038/s41598-020-58126-z

Kawamura, 2013, Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart, Circulation., 128, S87, 10.1161/CIRCULATIONAHA.112.000366

Thông tin
Thông tin xuất bản

Frontiers in Cardiovascular Medicine

Tập 9

Thông tin tác giả